Methylphenidate: Established and Expanding Roles in Symptom Management

American Journal of Hospice and Palliative Medicine

Volumn 29, Issue 6, 2012, Pages 483-490

  Prommer, Eric ^a  

^a MAYO CLINIC   (United States)

Author keywords

dopamine; fatigue; methylphenidate; opioid; psychostimulants; sedation

Indexed keywords

CENTRAL STIMULANT AGENT; METHYLPHENIDATE; NARCOTIC ANALGESIC AGENT;

ARTICLE; BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; COGNITION; COGNITIVE DEFECT; DEPRESSION; DRUG EFFECT; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; NEOPLASM; PALLIATIVE THERAPY; PSYCHOLOGICAL ASPECT;

ANALGESICS, OPIOID; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; COGNITION DISORDERS; DEPRESSION; FATIGUE; HIV INFECTIONS; HUMANS; METHYLPHENIDATE; NEOPLASMS; PALLIATIVE CARE;

EID: 84865088109     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909111427029     Document Type: Article

References (53)

1. Challman TD,Lipsky JJ.Methylphenidate: its pharmacology and uses.Mayo Clinic Proc. 2000;75 (7): 711-721.
2. Ding YS,Fowler JS,Volkow ND, et al.Chiral drugs: comparison of the pharmacokinetics of [11C] d-threo and l-threo-methylphenidate in the human and baboon brain.Psychopharmacology(Berl). 1997;131 (1): 71-78.
3. Madras BK,Pristupa ZB,Niznik HB, et al.Nitrogen-based drugs are not essential for blockade of monoamine transporters.Synapse. 1996;24 (4): 340-348.
4. Deutsch HM,Shi Q,Gruszecka-Kowalik E,Schweri MM.Synthesis and pharmacology of potential cocaine antagonists. 2. structure-activity relationship studies of aromatic ring-substituted methylphenidate analogs.J Med Chem. 1996;39 (6): 1201-1209.
5. Yano M,Steiner H.Methylphenidate and cocaine: the same effects on gene regulation?.Trends pharmacolo sci. 2007;28 (11): 588-596.
6. Han DD,Gu HH.Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.BMC Pharmacology. 2006;6 (1): 6.
7. Heal DJ,Pierce DM.Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.CNS Drugs. 2006;20 (9): 713-738.
8. Bymaster FP,Katner JS,Nelson DL, et al.Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat* 1: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.Neuropsychopharmacology. 2002;27 (5): 699-711.
9. Ishizuka T,Murakami M,Matsumoto R,Sakurai T,Yamatodani A.Histaminergic involvement in the wake-promoting effect of modafinil: in comparison with methylphenidate.J Pharmacol Sci. 2005;97 (suppl 1): 108.
10. Markowitz JS,Straughn AB,Patrick KS.Advances in the pharmacotherapy of attention-deficitûhyperactivity disorder: focus on methylphenidate formulations.Pharmacotherapy. 2003;23 (10): 1281-1299.
11. Srinivas NR,Hubbard JW,Korchinski ED,Midha KK.Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans.Pharm Res. 1993;10 (1): 14-21.
12. Patrick KS,Markowitz JS.Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder.Hum Psychopharmacol Clin Exp. 1997;12 (6): 527-546.
13. Birmaher B,Greenhill LL,Cooper TB,Fried J,Maminski B.Sustained release methylphenidate: pharmacokinetic studies in ADDH males.J Am Acad Child Adolesc Psychiatry. 1989;28 (5): 768.
14. Bukstein OG.Transdermal methylphenidate system: old wine in a new bottle.Expert Opin Drug Metab Toxicol. 2009;5 (6): 661-665.
15. Stiebel VG.Methylphenidate plasma levels in depressed patients with renal failure.Psychosomatics. 1994;35 (5): 498-500.
16. Delco F,Tchambaz L,Schlienger R,Drewe J,Krahenbuhl S.Dose adjustment in patients with liver disease.Drug Saf. 2005;28 (6): 529-545.
17. Kaufmann MW,Cassem N,Murray G,MacDonald D.The use of methylphenidate in depressed patients after cardiac surgery.J Clin Psychiatry. 1984;45 (2): 82-84.
18. Markowitz JS,Morrison SD,DeVane CL.Drug interactions with psychostimulants.Int Clin Psychopharmacol. 1999;14 (1): 1.
19. Lasheen W,Walsh D,Mahmoud F,Davis MP,Rivera N,Khoshknabi DS.Methylphenidate side effects in advanced cancer: a retrospective analysis.Am J Hosp Palliat Med. 2010;27 (1): 16-23.
20. Sarhill N,Walsh D,Nelson KA,Homsi J,LeGrand S,Davis MP.Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study.Am J Hosp Palliat Med. 2001;18 (3): 187-192.
21. Bruera E,Driver L,Barnes EA, et al.Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report.J Clin Oncol. 2003;21 (23): 4439-4443.
22. Chiarello RJ,Cole JO.The use of psychostimulants in general psychiatry: a reconsideration.Arch Gen Psychiatry. 1987;44 (3): 286-295.
23. Nathenson AL.Clinical evaluation of Ritalin.Dis Nerv Syst. 1956;17:392-396.
24. Fernandez F,Adams F.Methylphenidate treatment of patients with head and neck cancer.Head Neck Surg. 1986;8 (4): 296-300.
25. Fernandez F,Adams F,Holmes VF,Levy JK,Neidhart M.Methylphenidate for depressive disorders in cancer patients.Psychosomatics. 1987;28 (9): 455-461.
26. Olin J,Masand P.Psychostimulants for depression in hospitalized cancer patients.Psychosomatics. 1996;37 (1): 57-62.
27. Macleod AD.Methylphenidate in terminal depression.J Pain Symptom Manage. 1998;16 (3): 193-198.
28. Camacho A,Ng B.Methylphenidate for {alpha}-interferon induced depression.J Psychopharmacol. 2006;20 (5): 687-689.
29. Bruera E.Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain.Pain. 1992;48 (2): 163-166.
30. Bruera E,Chadwick S,Brenneis C,Hanson J,MacDonald RN.Methylphenidate associated with narcotics for the treatment of cancer pain.Cancer Treat Rep. 1987;71 (1): 67.
31. Bruera E,Fainsinger R,MacEachern T,Hanson J.The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report.Pain. 1992;50 (1): 75-77.
32. Bruera E,Brenneis C,Paterson AH,Neil MacDonald R.Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer.J Pain Symptom Manage. 1989;4 (1): 3-6.
33. Wilwerding MB,Loprinzi CL,Mailliard JA, et al.A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics.Support Care Cancer. 1995;3 (2): 135-138.
34. Weitzner MA,Meyers CA,Valentine AD.Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment.J Neuropsychiatry Clin Neurosci. 1995;7 (3): 347-350.
35. Meyers CA,Weitzner MA,Valentine AD,Levin VA.Methylphenidate therapy improves cognition, mood, and function of brain tumor patients.J Clin Oncolo. 1998;16 (7): 2522-2527.
36. Hinkin CH,Castellon SA,Hardy DJ,Farinpour R,Newton T,Singer E.Methylphenidate improves HIV-1-associated cognitive slowing.J Neuropsychiatry Clin Neurosci. 2001;13 (2): 248-254.
37. Bruera E,Driver L,Barnes EA, et al.Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report.J Clin Oncol. 2003;21 (23): 4439-4443.
38. Moraska AR,Sood A,Dakhil SR, et al.Phase III, Randomized, Double-blind, Placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 Trial.J Clin Oncol. 2010;28 (23): 3673.
39. Minton O,Richardson A,Sharpe M,Hotopf M,Stone PC.Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis.J Pain Symptom Manage. 2011;41 (4): 761-767.
40. Mendonτa DA,Menezes K,Jog MS.Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.Mov Disord. 2007;22 (14): 2070-2076.
41. Devos D,Krystkowiak P,Clement F, et al.Improvement of gait by chronic, high doses of methylphenidate in patients with advanced ParkinsonÆs disease.J Neurol Neurosurg Psychiatry. 2007;78 (5): 470-475.
42. Breitbart W,Rosenfeld B,Kaim M,Funesti-Esch J.A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease.Arch Intern Med. 2001;161 (3): 411-420.
43. Harel Y,Appleboim N,Lavie M,Achiron A.Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process.J Neurol Sci. 2009;276 (1-2): 38-40.
44. Gronwall DM.Paced auditory serial-addition task: a measure of recovery from concussion.Perceptual Mot Skills. 1977;44 (2): 367-373.
45. Herrmann N,Rothenburg LS,Black SE, et al.Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge.J Clin Psychopharmacol. 2008;28 (3): 296-301.
46. Ben-Itzhak R,Giladi N,Gruendlinger L,Hausdorff JM.Can methylphenidate reduce fall risk in community-living older adults? A double-blind, single-dose cross-over study.J Am Geriatr Soc. 2008;56 (4): 695-700.
47. Gagnon B,Low G,Schreier G.Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study.J Psychiatry Neurosci. 2005;30 (2): 100-107.
48. Masand P,Murray GB,Pickett P.Psychostimulants in post-stroke depression.J Neuropsychiatry Clin Neurosci. 1991;3 (1): 23-27.
49. Masand P,Chaudhary P.Methylphenidate treatment of poststroke depression in a patient with global aphasia.Ann Clin Psychiatry. 1994;6 (4): 271-274.
50. Wroblewski BA,Leary JM,Phelan AM,Whyte J,Manning K.Methylphenidate and seizure frequency in brain injured patients with seizure disorders.J Clin Psychiatry. 1992;53 (3): 86-89.
51. Vigano A,Watanabe S,Bruera E.Methylphenidate for the management of somatization in terminal cancer patients.J Pain Symptom Manage. 1995;10 (2): 167-170.
52. Dalal S,Melzack R.Psychostimulant drugs potentiate morphine analgesia in the formalin test.J Pain Symptom Manage. 1998;16 (4): 230-239.
53. Methylphenidate. http://www.drugstore.com. 2011.